Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
You may also be interested in...
ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative
FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.
ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative
FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.
Lilly Contract Sales Team Will Hit The Diabetes Market “Within Weeks”
The contract team will also be cross-trained on other Lilly products.